Lapatinib and Bortezomib in Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01497626
Recruitment Status : Terminated (Drug support withdrawn)
First Posted : December 22, 2011
Last Update Posted : February 17, 2016
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Georgetown University

Brief Summary:

This study is for patients with an advanced type of cancer for which no curative treatment exists.

The purpose of this study is to test the safety and efficacy of the combination of the study drugs, lapatinib and bortezomib. Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. By inhibiting these proteins, lapatinib can inhibit cancer cell growth and even lead to their death. Lapatinib is an oral pill given by mouth once every day. Lapatinib is approved by the FDA for patients with breast cancer.

Bortezomib is a drug that targets a part of cancer cells known as the proteosome. By inhibiting the proteosome, bortezomib can inhibit cancer cell growth and even lead to their death. Bortezomib is given intravenously, once a week, 2 out of every 3 weeks. Bortezomib is approved by the FDA for patients with multiple myeloma and mantle cell lymphoma.

This research is being done because it is not known if the combination of lapatinib and bortezomib will work better than lapatinib or bortezomib alone, although in the lab and in animal studies the combination of the two drugs was much more effective than either drug alone.

As part of this study biopsies will be taken of patients' tumors before any treatment, after starting lapatinib alone, and after receiving both lapatinib and bortezomib. Investigators want to study what markers inside tumors may relate to how well these two medications work. These biopsies are required as part of the study.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: Lapatinib and bortezomib Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies
Study Start Date : September 2011
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bortezomib plus lapatinib
Combination treatment with lapatinib and bortezomib
Drug: Lapatinib and bortezomib

Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.

Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts.

Other Name: Velcade

Primary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: 18 months ]
    The highest dose at which </= 1 out of 6 subjects has a dose-limiting toxicity

Secondary Outcome Measures :
  1. toxicity [ Time Frame: 18 months ]
    Adverse events seen during the trial graded using CTCAE version 4

  2. Response rate [ Time Frame: 18 months ]
    complete response and partial response measured by RECIST 1.1

  3. Disease control rate [ Time Frame: 2 months ]
    stable disease after two cycles+ partial response + complete response as determined by RECIST 1.1 criteria

  4. Pharmacodynamics [ Time Frame: pre-treatment, after 1 week of therapy and adter 3 weeks of therapy ]
    To assess changes in the following in serial tumor samples: EGFR, HER2, HER3, AKT, Actin, ERK, GSK3a-beta, IGF-1R, MEK 1/2, mTOR, p70S6, P13K, PTEN, SHC Y317, NFKB, IKB, CFK4, CDK2, cyclin D1, cyclin A, Cyclin E, p15, p16, p21, p27, beta-catenin, and ras gene mutation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven malignant solid tumor with measurable disease
  • Progression on, or intolerance of, or ineligibility for all standard therapies
  • Biopsy accessible tumor deposits
  • LVEF >/= institutional normal
  • Corrected QT interval less than 500 milliseconds by EKG
  • ECOG performance status 0-2
  • Subjects with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intercranial disease and have not had treatment with steroids within 1 week of enrollment.
  • Adequate hepatic, bone marrow, and renal function
  • Partial thromboplastin time must be </= 1.5 x upper limit of institution's normal range and INR < 1.5. Subjects on anticoagulants will be permitted to enroll as long as the INR is in the acceptable therapeutic range.
  • Life expectancy > 12 weeks
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months.
  • Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the informed consent form.

Exclusion Criteria:

  • Patients with lymphomas
  • CNS metastases which do not meet the criteria outlines in the inclusion criteria
  • Peripheral neuropathy >/= Grade 2 at baseline or peripheral neuropathy >/= Grade 1 with neuropathic pain
  • Active severe infection or known chronic infection with HIV or hepatitis B virus
  • Cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months
  • Life-threatening visceral disease or other severe concurrent disease
  • Women who are pregnant or breastfeeding
  • Anticipated patient survival under 3 months
  • Concurrent use of known CYP 3A4 inhibiting or activating medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01497626

United States, District of Columbia
Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Millennium Pharmaceuticals, Inc.
Principal Investigator: Michael Pishvaian, MD PhD Georgetown University

Responsible Party: Georgetown University Identifier: NCT01497626     History of Changes
Other Study ID Numbers: 2010-533
XO5371 ( Other Identifier: Millennium Pharmaceuticals )
8LAP114999 ( Other Identifier: GlaxoSmithKline )
First Posted: December 22, 2011    Key Record Dates
Last Update Posted: February 17, 2016
Last Verified: September 2015

Keywords provided by Georgetown University:
Advanced cancer
Solid tumor

Additional relevant MeSH terms:
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action